[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612596":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":22,"locations":28,"responsibleParty":105,"collaborators":10,"id":107,"slug":108,"hasResults":109,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":10,"eligibilityCriteria":113,"healthyVolunteers":109,"sex":114,"minAge":115,"maxAge":10,"enrollmentInfo":116,"targetDuration":10,"studyType":119,"phases":10,"briefSummary":120,"conditions":121,"keywords":123,"overallStatus":31,"whyStopped":10,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":139},{"fullName":5,"class":6},"Blueprint Medicines Corporation","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Avapritinib",null,"Participants will receive avapritinib as part of their treatment plan with their healthcare practitioner (HCP) and in accordance with the Summary of Product Characteristics (SmPC).",[13],"Drug: Avapritinib",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Avapritinib will be administered as an oral tablet.",[9],[20,21],"Ayvakyt","BLU-285",[23],{"name":24,"role":25,"phone":26,"phoneExt":10,"email":27},"Blueprint Medicines, EU Contact","CONTACT","+31 85 064 4001","medinfoeurope@blueprintmedicines.com",[29,42,51,60,69,78,87,96],{"facility":30,"status":31,"city":32,"state":10,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":10},"Charité Universitätmedizin Berlin, Klinik für Dermatologie, Venerologie und Allergologie","RECRUITING","Berlin","10117","Germany","DE",{"type":37,"coordinates":38},"Point",[39,40],13.41053,52.52437,{"lat":40,"lon":39},{"facility":43,"status":31,"city":44,"state":10,"zip":45,"country":34,"countryCode":35,"cosmosGeoPoint":46,"geoPoint":50,"contacts":10},"Katholisches Klinikum Bochum","Bochum","44791",{"type":37,"coordinates":47},[48,49],7.21648,51.48165,{"lat":49,"lon":48},{"facility":52,"status":31,"city":53,"state":10,"zip":54,"country":34,"countryCode":35,"cosmosGeoPoint":55,"geoPoint":59,"contacts":10},"MVZ Klinikum Deggendorf","Deggendorf","94469",{"type":37,"coordinates":56},[57,58],12.96068,48.84085,{"lat":58,"lon":57},{"facility":61,"status":31,"city":62,"state":10,"zip":63,"country":34,"countryCode":35,"cosmosGeoPoint":64,"geoPoint":68,"contacts":10},"Universitätsklinikum Carl Gustav Carus Dresden Klinik und Poliklinik für Dermatologie","Dresden","01307",{"type":37,"coordinates":65},[66,67],13.73832,51.05089,{"lat":67,"lon":66},{"facility":70,"status":31,"city":71,"state":10,"zip":72,"country":34,"countryCode":35,"cosmosGeoPoint":73,"geoPoint":77,"contacts":10},"University Medical Center Goettingen - Georg August University of Goettingen","Göttingen","37075",{"type":37,"coordinates":74},[75,76],9.93228,51.53443,{"lat":76,"lon":75},{"facility":79,"status":31,"city":80,"state":10,"zip":81,"country":34,"countryCode":35,"cosmosGeoPoint":82,"geoPoint":86,"contacts":10},"Universitats-Hautklinik Tubingen, Studienzentrum lmmundermatologie","Tübingen","72076",{"type":37,"coordinates":83},[84,85],9.05222,48.52266,{"lat":85,"lon":84},{"facility":88,"status":31,"city":89,"state":10,"zip":90,"country":34,"countryCode":35,"cosmosGeoPoint":91,"geoPoint":95,"contacts":10},"HNO-Gemeinschaftspraxis Wiesbaden, GEKA Gesellschaft für Experimentelle und Klinische Atemwegsforschung mbH, Zentrum für Rhinologie und Allergologie","Wiesbaden","65205",{"type":37,"coordinates":92},[93,94],8.24435,50.08601,{"lat":94,"lon":93},{"facility":97,"status":31,"city":98,"state":10,"zip":99,"country":34,"countryCode":35,"cosmosGeoPoint":100,"geoPoint":104,"contacts":10},"Helios Universitätsklinikum Wuppertal","Wuppertal","42283",{"type":37,"coordinates":101},[102,103],7.14816,51.25627,{"lat":103,"lon":102},{"type":106,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100612596","a-non-interventional-study-in-participants-with-indolent-systemic-mastocytosis-ism-in-germany-100612596",false,"NCT07255638","A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany","A Prospective Non-Interventional Study to Describe the Effectiveness of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis and Symptoms That Are Not Adequately Controlled With Symptomatic Treatments in Real-World Settings","Inclusion Criteria:\n\n* Participants is starting avapritinib treatment at the HCP's discretion as part of their routine care (for ISM with moderate to severe symptoms inadequately controlled with symptomatic treatment) and in accordance with approved SmPC.\n\nExclusion Criteria:\n\n* Participant with a potential increased risk for intracranial hemorrhage including those with a history of vascular aneurysm, intracranial hemorrhage, cerebrovascular accident within the prior year, or severe thrombocytopenia.\n* Participant who has previously taken avapritinib as a commercial drug or as part of a clinical study.","ALL","18 Years",{"count":117,"type":118},80,"ESTIMATED","OBSERVATIONAL","This is a non-interventional study assessing the effectiveness of avapritinib (BLU-285) in the management of ISM in real-world settings in Germany. The study also seeks to address the existing data gap in the natural history and management of participants with ISM.\n\nThe study is designed to follow each participant up to a maximum of 24 months.",[122],"Indolent Systemic Mastocytosis",[124,125,9,21,126,127,128,129],"ISM","Indolent systemic mastocytosis","Selective KIT mutation-targeted tyrosine kinase inhibitor","Tyrosine kinase inhibitor","Mastocytosis","Neoplastic mast cells","2026-04-17",{"date":132,"type":133},"2026-04-20","ACTUAL",{"date":135,"type":133},"2025-12-09",{"date":137,"type":118},"2028-12-01",{"name":5,"class":6},8]